APC-Labeled Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein

用户评价
货号-规格
价格
Qty.
HLW-HA2H6-25ug
¥4160.00
HLW-HA2H6-200ug (100ug X 2)
¥23940.00
合计0件 产品金额¥ 0

产品详情

  • 分子别名(Synonym)

    HLA-A*0201 & B2M & WT-1 (RMFPNAPYL)

  • 表达区间及表达系统(Source)

    APC-Labeled Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein (HLW-HA2H6) is expressed from human 293 cells (HEK293). It contains AA Gly 25 - Ile 308 (HLA-A*02:01) & Ile 21 - Met 119 (B2M) & RMFPNAPYL peptide (Accession # AAA59606.1 (HLA-A*02:01) & P61769 (B2M) & RMFPNAPYL).

    Predicted N-terminus: Gly 25 & Ile 21

  • 蛋白结构(Molecular Characterization)

    APC-Labeled Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Tetramer Protein is assembled by biotinylated monomer (HLW-H82E5) and APC-labeled streptavidin.

    Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein is produced by co-expression of HLA and B2M loaded with WT-1 peptide. Biotinylated Human HLA-A*02:01&B2M&WT-1 (RMFPNAPYL) Complex Protein carries a polyhistidine tag at the C-terminus, followed by an Avi tag (Avitag™).

  • 偶联(Conjugate)

    APC

    Excitation Wavelength: 640 nm

    Emission Wavelength: 661 nm

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in PBS, 1% BSA, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please protect from light and avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

用户评价
发表评论

背景介绍

Wilms tumor gene 1 (WT1),is an attractive target antigen for leukemia and solid cancer. WT1-specific adoptive immunotherapy has developed for tumor treatment in recent years. WT1 has been proved wildly expressed in breast, colon and ovarian cancer. It participates in cell growth, differentiation and apoptosis regulation. The WT1127-134 (RMFPNAPYL) was shown to be recognized by HLA-A*0201 tumor-infiltrating lymphocytes from melanoma patients, and therefore it is widely been studied in TCR-T studies. The Human HLA-A*0201 WT-1 (RMFPNAPYL) complex Protein is a complex of HLA-A*0201 of the MHC Class I, B2M and RMFPNAPYL peptide of the WT-1.

前沿进展

 
联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 用户评价
  • 背景介绍